Back to Search Results
Study Complete
Sponsor ID
20030133

Evaluating Aranesp® in Subjects with End Stage Renal Disease onChronic Hemodialysis

Sponsor ID
20030133
Clinicaltrials.gov ID
NCT00117104
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once

weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are

either recombinant human erythropoietin (rHuEPO) naïve or subjects converted

from rHuEPO therapy administered IV thrice weekly (TIW).

Additional Study Details

Phase
Phase 4
Product
darbepoetin alfa
Type
Interventional
Masking
None (Open Label)
Enrollment
N/A
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Kidney Disease
    • Sex
    All
    Trial Dates
    Jun 2003 - N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subjects with end stage renal disease (ESRD) on hemodialysis
    Exclusion Criteria:
    - Known hypersensitivity to Aranesp® (darbepoetin alfa) or any of its excipients - Participating in an investigational drug or device trial - Patient will not be available for follow-up assessment - Patient has any disorder that compromises the ability of the patient to give written informed consent and/or to comply with study procedures